Summary: We initiated a phase 2 trial with a combination of topotecan and etoposide (TE) in patients with relapse after intensive first line chemotherapy for neuroblastoma. TE chemotherapy consisted of topotecan (schedule A: 1.0 mg/m 2 /d 30-minute-infusion days 1 to 5, B: 0.7 mg/m 2 /d continuous infusion days 1 to 7, and C: 1.0 mg/m 2 /d continuous infusion days 1 to 7) followed by etoposide (100 mg/m 2 /d 1-hour-infusion days 8 to 10). TE was repeated every 28 days. The treatment was continued until severe nonhematopoietic toxicity or progression occurred or the treating physician chose alternative consolidation treatment after response to TE. Forty patients received 153 TE cycles. Grades 3 to 4 leukopenia was frequently observed in all schedules (A 51% of cycles, B 48%, and C 74%, P = 0.141). Thrombocytopenia (A 69%, B 63%, and C 93%, P = 0.004) and neutropenic fever (A 12%, B 29%, and C 37%, P = 0.048) occurred more frequently in schedule C. No treatment-related fatal toxicity was observed. Among 36 patients evaluable for response, 4 patients achieved complete and 13 patients achieved partial remission (47%). We conclude that the combination of TE is effective and tolerable in the treatment of relapsed high-risk neuroblastoma.
Summary: We initiated a phase 2 trial with a combination of topotecan and etoposide (TE) in patients with relapse after intensive first line chemotherapy for neuroblastoma. TE chemotherapy consisted of topotecan (schedule A /d continuous infusion days 1 to 7) followed by etoposide (100 mg/m 2 /d 1-hour-infusion days 8 to 10). TE was repeated every 28 days. The treatment was continued until severe nonhematopoietic toxicity or progression occurred or the treating physician chose alternative consolidation treatment after response to TE. Forty patients received 153 TE cycles. Grades 3 to 4 leukopenia was frequently observed in all schedules (A 51% of cycles, B 48%, and C 74%, P = 0.141). Thrombocytopenia (A 69%, B 63%, and C 93%, P = 0.004) and neutropenic fever (A 12%, B 29%, and C 37%, P = 0.048) occurred more frequently in schedule C. No treatment-related fatal toxicity was observed. Among 36 patients evaluable for response, 4 patients achieved complete and 13 patients achieved partial remission (47%). We conclude that the combination of TE is effective and tolerable in the treatment of relapsed high-risk neuroblastoma. P atients with relapse after high intensive treatment for high-risk neuroblastoma only have a small chance of long-term survival. 1 To manage relapsed patients and to improve the first line therapy, new treatment strategies are still needed. Topotecan (Hycamtin GlaxoSmithKline) acts as topoisomerase I inhibitor. [2] [3] [4] It proved to be effective in neuroblastoma xenografts in mice [5] [6] [7] and was found tolerable in phase 1 to 2 trials with different application schedules. [8] [9] [10] [11] [12] [13] [14] [15] [16] Main side effects were myelosupression, nausea, vomiting, and mucositis. A combination of topotecan and etoposide (TE) can increase the cytotoxic effect by inhibition of topoisomerase II and I. Sequential application of topotecan followed by etoposide was found to be more effective because topoisomerase I and II are expressed reciprocally. [17] [18] [19] [20] [21] [22] Numerous clinical trials demonstrated feasibility and efficacy of such combinations and found myelotoxicity and mucositis as main side effects. [23] [24] [25] [26] [27] [28] [29] [30] [31] We reported earlier that topotecan monotherapy (1.0 mg/m 2 /d for 5 d) is an effective palliative treatment. 12 Hence, we initiated a trial of TE in the treatment of patients with relapse of high-risk neuroblastoma. Because protracted topotecan administration was found more effective 5, 16 and central nervous system penetration is time dependent, 32 the dose used in the previous trial 12 was spread as continuous infusion over 7 days (schedule B). After toxicity seemed acceptable, a higher dose of topotecan (1 mg/m 2 /d for 7 d) was applied (schedule C). Patients who refused continuous infusion or had no central line were allowed for daily topotecan on 5 sequential days (1 mg/m 2 /d for 5 d, schedule A). Primary objective of this trial was toxicity. Secondary objective was response. . Each patient was assigned to one schedule. The TE cycles were repeated every 28 days if the bone marrow reconstitution was complete, that is, neutrophiles count >500/mL and platelets >50,000/mL (unless bone marrow infiltration caused aplasia). If severe bone marrow or any other toxicity delayed the start of the next cycle more than 30 days, dose reduction by 33% of either etoposide (group B) or topotecan (groups A and C) was recommended. If the reduced dose cycle again led to delay >30 days, additional reduction of the corresponding drug by 33% (topotecan in group B and etoposide in groups A and C) was recommended. The use of granulocyte colonystimulating factor (G-CSF) was not planned in the trial but was allowed if the treating physicians choose to administer G-CSF as part of the supportive care.
PATIENTS AND METHODS

Patient Selection
The TE treatment had to be discontinued if progression or severe nonhematopoietic toxicity was observed or if the treating physician decided to continue with additional treatment elements for consolidation of response achieved by TE chemotherapy. Response to TE was assessed as the best tumor status achieved after a variable number of cycles.
Assessment
All patients underwent complete staging including clinical status, tumor markers, imaging, MIBG scintigraphy, and bone marrow aspirates at trial entry. Clinical status, tumor markers, and ultrasound were assessed before each TE cycle. Toxicity was monitored continuously by clinical examination and routine blood analysis at least every 2 to 4 days during and after each cycle. Toxicity symptoms were documented and reported according to the National Cancer Institute Common Toxicity Criteria Version 2.0 (http://ctep.cancer.gov).
Response assessment was adapted according to the pattern of relapse, that is, all abnormal tests had to be repeated during the trial. If progression was suspected, additional investigations were required regardless of the results at trial entry. According to the International Neuroblastoma Staging System criteria, 33 response was defined as complete response, very good partial response, partial response, stable disease, and progressive disease. Follow-up data were collected by the German neuroblastoma trial office because all patients were registered and received first line treatment according to the German neuroblastoma trials NB90 and NB97.
Statistics
Topotecan dose escalation (0.7 mg/m 2 /d to 1.0 mg/ m 2 /d) was planned if no extramedullary grade 4 toxicity was seen in the first 10 patients. Patients who received topotecan as 30-minute-infusion were included in this analysis for descriptive reasons. A minimum of 5 responses in 35 patients was required to assume effectiveness of the treatment (P 0 = 0.10, P 1 = 0.30, a = 0.10, and b = 0.10, where P 0 is the uninteresting response level and P 1 is the desirable response level). 34 
RESULTS
Patients' Characteristics
A total of 40 patients received 153 TE cycles during relapse treatment. Thirty-eight patients were considered high-risk at the time of diagnosis (stage 4 n = 30, stage 3 without MYCN amplification n = 3, stage 3 with MYCN amplification n = 3, 1 patient with MYCN positive stage 2, 1 patient with MYCN positive stage 4S, and 1 patient with multilocular neuroblastoma). All patients had either received etoposide containing standard-risk (n = 3) or high-risk treatment (n = 37) according to the German multicenter trials NB90 and NB97 (for chemotherapy details see Refs. 35, 36) . Twelve patients had undergone myeloablative chemotherapy with autologous stem cell transplantation during initial treatment. No patient had received topotecan or any other second line protocol before trial entry. Thirteen children were treated for local relapse and 27 for metastatic relapse (with or without local tumor recurrence).
The 40 patients included in the trial were assigned to one schedule at trial entry. Individual dose escalation was not planned. Three patients switched the schedule: they started with schedule B, C, and B and after uneventful cycles proceeded with schedule C, B, and topotecan monotherapy, respectively. They remained in the analysis because toxicity was analyzed according to the chemotherapy schedule the patients received and outcome was analyzed on overall basis. The characteristics of the 40 trial patients are found in Table 1 . The median age at first diagnosis of neuroblastoma was 3.1 years (range 0.4 to 37.1 y). The median age at the first TE cycle was 5.5 years (range 1.4 to 39.8 y).
Toxicity (Table 2)
A total of 153 TE cycles were applied. Twelve cycles were excluded from toxicity analysis because documentation was not sufficient. Therefore, 141 cycles were evaluable for toxicity (Fig. 1) . Drug doses were reduced as recommended by the protocol during 34 of 141 cycles. Bone marrow toxicity was considerable: grades 3 to 4 leukopenia was frequently observed in all 3 schedules (schedule A 51%, B 48%, and C 74%, w 2 test P = 0.141). The median time from start of chemotherapy to leukocyte nadir was 16 days. The interval was shorter after schedule A (median 14 d) compared with schedule B (16 d) and C (18 d, Kruskal-Wallis test P<0.001). Grades 3 to 4 thrombocytopenia occurred more frequently in schedule C (93%) compared with B (63%) and A (69%, w 2 test P = 0.004). The time interval between start of the chemotherapy cycle and the platelet nadir was similar after schedules A and C (14 d) but longer after schedule B (16 d, Kruskal-Wallis test P = 0.001). Due to bone marrow depression, 12% of schedule A cycles, 29% of schedule B, and 37% of schedule C were followed by neutropenic fever requiring additional hospital treatment (w 2 test P = 0.048). Cultures were negative with 2 exceptions: one 6-year-old patient experienced facial soft tissue aspergillosis and severe enterocolitis during neutropenia after the first TE cycle according to schedule C. He required intensive care and recovered. Anticancer treatment was continued with low-dose oral topotecan. He died 3.9 months after the last TE cycle due to disease progression. One 5-year-old patient with relapse 13 months after ASCT developed fungal pneumonia after the second TE cycle according to schedule C. The infection was managed successfully. The patient received palliative treatment with 13-cis-retinoic acid and died 11 months after the last TE cycle due to progressive disease. All other neutropenia-associated febrile episodes were managed successfully by intravenous antibiotic treatment.
No fatal infection or any other fatal toxicity occurred. G-CSF administration was documented during 13 cycles (1 schedule A, 1 schedule B, and 10 during schedule C). This small number does not allow conclusions regarding the effect of G-CSF on the frequency of febrile neutropenia. Red blood cell toxicity was not registered during the trial because packed red cell transfusions were considered as unavoidable after effective chemotherapy.
Response and Outcome
The patients received a median number of 3 TE cycles (range 1 to 12) before they either experienced progression or received other treatment elements. Four patients underwent complete resection after localized relapse and, therefore, were not evaluable for response. Among 36 patients with measurable disease at trial entry, 4 (11%) achieved complete and 13 (36%) achieved partial remission after treatment with a median number of 4 TE cycles (range 2 to 8). The total response rate (complete response+partial response) was 47%, the 95% confidence interval 30% to 65%. The response was diagnosed differently because of the very individual relapse pattern of these 17 patients showing objective response: imaging showed clear shrinkage of a solid tumor in 13 of 16 patients, intensity and/or number of MIBG positive lesions decreased in 5 of 7 patients, bone marrow infiltration was completely cleared in 3 of 4 patients with bone marrow involvement. The response rate was better if the patients had not undergone ASCT during first line treatment. Only 2 of 10 patients with previous ASCT achieved complete or partial remission after TE treatment compared with 9 of 26 patients who had not undergone first line ASCT (Fisher exact test P = 0.025). The response rate was not influenced by initial treatment protocol (w 2 test P = 0.679), by TE schedule (w 2 test P = 0.339), by presence of MYCN amplification (Fisher exact test P = 1.000), by localized versus metastatic disease at first diagnosis (Fisher exact test P = 0.516), or by presence of local or metastatic disease at relapse (Fisher exact test P = 0.281). The mean progression-free survival interval of the 17 patients who responded to TE chemotherapy was 421 days (range 55 to 1188 d). During the progression-free interval, some patients received additional treatment elements after TE response assessment. As of June 2006, 31 of 40 patients have died due to disease progression, 1 is alive with active disease, 6 are in complete remission, and 2 are in partial remission. Among the patients who died, 11 had initially responded to TE chemotherapy, 18 had shown no response, and 2 patients had not been evaluable after complete resection.
DISCUSSION
This trial found the combination of TE to be tolerable in heavily pretreated relapsed neuroblastoma patients. The patient population was heterogeneous for (1) distribution of clinical and molecular risk factors, (2) relapse pattern, and (3) primary treatment but all patients were clearly high-risk. This heterogeneity must be considered while interpreting particularly the response data.
No unexpected toxicity was observed but bone marrow depression was considerable. Some patients developed fever during neutropenia and were admitted to the hospital for intravenous antibiotic therapy. Although the frequency of neutropenia was not different between the 3 drug schedules, the duration of neutropenia and the incidence of neutropenic fever clearly were higher after schedule C. Of note, patients receiving schedule A had no central venous access as possible focus of infection. With 2 exceptions, cultures taken during fever 34 Comparison of the 3 schedules by w 2 test did not identify differences in the response rate because the patient numbers were too small. Long-term follow-up demonstrated that response is not correlated with outcome: 11 TE responders later experienced disease progression and died due to tumor progression. But the long median progression-free interval of 421 days (55 to 1188 d) indicates that TE is an effective palliative treatment.
Response and outcome results in relapsed neuroblastoma patients cannot be simply translated into response data in newly diagnosed patients because tumor cells acquire drug resistance during chemotherapy. 41 Further, cross-resistance between etoposide and topotecan has been reported. 42, 43 Therefore, one can expect better long-term outcome using topotecan containing first line chemotherapy regimens.
The combination of TE was tolerable in relapsed neuroblastoma patients even in schedule C. No treatment-related death occurred in any schedule. Response data are encouraging. But finally, 31 patients died due to disease progression. This indicates that response and outcome are not closely correlated in relapsed malignant disease. Because we expect better long-term results using a high-dose intensity, we chose schedule C for further trials. Based on preclinical data, an alkylating compound was added. The German neuroblastoma study group already has finished a phase 2 trial TE schedule C combined with cyclophosphamide in the treatment of relapsed neuroblastoma. This 3-drug-combination is currently assessed in a phase 3 trial in newly diagnosed neuroblastoma patients.
APPENDIX
The following investigators and centers participated in the trial: A Gnekow (Augsburg), K Rager (Bad Mergentheim), P Harms (Bad Oeynhausen), H-J Spaar (Bremen), W Do¨rffel, R Fengler (Berlin), U Bode (Bonn), T Wiesel (Datteln), U Go¨bel (Dusseldorf), A Lemmer (Erfurt), B Kremens (Essen), A Reiter (GieXen), A Wawer (Halle), K Welte (Hanover), N Graf (Homburg/Saar), A Sauerbrey (Jena), M Wright (Kassel), S Vo¨lpel (Krefeld), P Klose, I Schmid (Munich), A Jobke, M Schwarzer (Nuremberg), H-G Scheel-Walter (Tubingen), F Schilling (Stuttgart), and J Ku¨hl (Wu¨rzburg).
